Pliant Therapeutics shareholders elect Coulie, Crowell, Krognes as Class III directors

• Pliant Therapeutics held its annual stockholders meeting on June 11, 2026.
• Stockholders backed the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• A non-binding advisory resolution on executive pay received stockholder support.
• Stockholders also approved the slate of Class III director nominees for terms running to the 2029 annual meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001746473-26-000092), on June 11, 2026, and is solely responsible for the information contained therein.